ArticleDermatology and therapy2025
Incidence of Conjunctivitis and Keratitis Among Individuals with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab in the United States: a Cohort Study in Routine Care Based on Healthcare Claims.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between Dupilumab and Ocular Surface Diseases in Children.Ophthalmology science · 2026Article
- Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.International journal of dermatology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn clinical trials of patients with atopic dermatitis (AD), conjunctivitis and keratitis occurred more frequently with dupilumab than placebo. Studies using real-world data have also shown a higher incidence with dupilumab but did not use validated algorithms to identify the population and outcomes. The objective of this study was to investigate the incidence of conjunctivitis and keratitis among patients with moderate-to-severe AD treated with dupilumab relative to dupilumab-naïve patients in a real-world setting using validated algorithms.
methodsA retrospective observational cohort study was conducted in an insurance claims database using validated algorithms for moderate-to-severe AD and ocular outcomes. Initiators of dupilumab were identified and propensity score (PS) matched with dupilumab-naïve patients with moderate-to-severe AD. Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for conjunctivitis and keratitis during follow-up were estimated using Poisson regression.
resultsAmong 13,790 patients in the moderate-to-severe AD study population, 2175 dupilumab initiators and 2189 dupilumab-naïve patients were included in the analysis. Dupilumab was associated with an increased risk of conjunctivitis (IRR = 1.86 [95% CI 1.51-2.30]) and keratitis (IRR = 4.06 [95% CI 1.70-9.68]) compared to patients with moderate-to-severe AD not receiving dupilumab. The cumulative 1-year risk of conjunctivitis was 15.8% and 8.4% in the dupilumab and dupilumab-naïve cohorts, respectively; the cumulative 1-year risk of keratitis was 1.3% and 0.2%, respectively.
conclusionStudy findings are consistent with safety data from clinical trials and existing literature. However, a few keratitis events were observed, and post hoc analyses suggested residual confounding might be present. The known benefit-risk profile for dupilumab remains unchanged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.